Magnetic stimulation of carotid sinus as a treatment for hypertension

Previously, we reported that magnetic stimulation of carotid sinus (MSCS) could lower arterial pressure in rabbits. In this randomized, sham‐controlled pilot study, we evaluated the effects of MSCS on blood pressure in pre‐hypertensive and hypertensive subjects. A total of 15 subjects with blood pressure higher than 130/80 mm Hg were randomized to receive sham or 1Hz MSCS. The changes of systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MAP) during treatment were compared between groups. The heart rate variability (HRV) and baroreflex sensitivity (BRS) before, during, and after treatments were analyzed. Reduction of SBP was significantly greater in subjects with MSCS than those with sham stimulation (6.6 ± 0.4 vs −2.5 ± 0.4 mm Hg, P < 0.001). Reduction of DBP was significantly greater in subjects with MSCS than those with sham stimulation (1.2 ± 0.2 vs −2.8 ± 0.2 mm Hg, P < 0.001). Reduction of MAP was significantly greater in subjects with MSCS than those with sham stimulation (1.4 ± 0.3 mm Hg vs −4.0 ± 0.3 mm Hg, P < 0.001). Reduction of HR was significantly greater in subjects with MSCS than those with sham stimulation (0.5 ± 0.5 vs −1.9 ± 0.3 beats/min, P = 0.002). BRS increased from 6.85 ± 0.77 to 8.79 ± 0.95 ms/mm Hg after MSCS compared with that at baseline (P = 0.027). Thus, MSCS can lower blood pressure and heart rate in pre‐hypertensive and hypertensive subject, warranting further study for establishing MSCS as a treatment for hypertension.     

Endovascular stenting for atherosclerotic subclavian artery stenosis in patients with other craniocervical artery stenosis

Atherosclerotic subclavian artery stenosis (SAS) accompanied with other craniocervical artery stenosis (OCAS) is not uncommon in practice. We sought to investigate the safety and efficacy of endovascular stenting for SAS in patients with OCAS. Between January 2004 and February 2012, 71 consecutive atherosclerotic SAS patients who underwent primary stenting in our medical center were included. The enrolled patients were divided into combined-SAS group (n = 51) and solitary-SAS group (n = 20) depending on the presence or absence of OCAS. Data of demographics, procedure, and the followed-up were retrieved and analyzed. The technical success rate was 95.8 %; the clinical success rate was 90.1 %. There was no catheter-related major stroke or death. The immediate outcomes had no statistical difference between groups. During a mean of 27 ± 20 months (range 2–88 months) followed-up, 7(10.3 %) restenosis and 12(17.6 %) clinical events were identified. The primary patency rate was 95.3, 84.9 and 84.9 % at 12, 24 months, and final followed-up respectively, which had no statistical difference between groups (odds ratio (OR), 2.60; 95 % confidence interval (CI), 0.54–12.53; P = 0.232). The overall clinical event-free survival rate was 93.5, 86.2 and 54.6 %, respectively, where the result of combined-SAS group was inferior to that of the solitary-SAS group (OR, 3.34; 95 % CI, 1.02–11.00; P = 0.047). Endovascular stenting was safe and feasible for atherosclerotic SAS in patients with OCAS, although the combined OCAS may have a significant influence on the long-term outcome. Further studies are warrant to investigate the effects of revascularization for multiple craniocervical artery stenoses on the cerebral hemodynamics and long-term outcomes.     

Influence of Vessel Size and Tortuosity on In-stent Restenosis After Stent Implantation in the Vertebral Artery Ostium

Purpose  

Percutaneous transluminal angioplasty and stenting is emerging as an alternative for treating atherosclerotic stenosis in the vertebral artery ostium. However, in-stent restenosis (ISR) still remains a critical issue to be addressed. Little is known about the relationship between anatomic characteristics of the artery and ISR after stent implantation. In this study, we have evaluated influential factors for ISR in a cohort of the patients with stenting in the vertebral artery ostium.     

现时生存分析方法的应用实践与评价

目的利用林州市肿瘤登记处的资料,应用现时生存分析方法计算食管癌、胃癌的5年相对生存率,并与传统的队列方法比较,评价现时生存分析方法在预测癌症患者长期生存率时的应用价值。方法分别利用队列、完全生存分析和现时生存分析方法计算食管癌、胃癌的5年相对生存率,与随访5年后得到的实际生存率进行比较,以三种方法计算的数据与实际值的绝对差值平方评估差异的大小。结果应用队列、完全生存分析和现时生存分析方法计算林州市食管癌的5年相对生存率分别为28.00%、32.08%、36.67%,胃癌23.19%、29.03%、33.98%,食管癌和胃癌的实际5年相对生存率分别为36.82%和34.04%。三种方法计算的结果与实际生存率差异的平方分别是196、48、0。结论现时生存分析方法得到的5年相对生存率与实际值最为接近,能及时地反映现时癌症诊治的水平与效果,可以作为评估癌症长期生存指标的一种统计方法。     

猪小肠黏膜下层脱细胞修复补片修复手部软组织缺损的效果分析

目的 对比应用新型再生可降解生物材料猪小肠黏膜下层脱细胞修复补片(SIS)与植皮术在修复手部软组织缺损的治疗效果.方法 2017年12月至2018年12月,共收治手部软组织缺损36例,根据缺损面积与治疗方法分为两组:补片组21例,软组织缺损面积2.0 cm×1.5 cm^9.0 cm×3.5 cm,平均5.3 cm×2.1 cm,采用SIS治疗;植皮组15例,软组织缺损面积9.0 cm×4.0 cm^16.0 cm×9.0 cm,平均12.0 cm×8.5 cm,采用中厚皮片植皮治疗.观察两组治疗方法促进软组织缺损愈合的效果,记录术后14 d、21 d、28 d、3个月创面区愈合情况,并随访评估创面区愈合后的外观、色泽、弹性、感觉恢复与部分肌腱外露的治疗效果.结果 本组36例均获随访,随访时间3~10个月,平均5个月.两组创面均完全愈合,外观、色泽接近,皮肤弹性及感觉均恢复良好.补片组感觉恢复优14例(66.6%),良5例(23.8%),差2例(9.6%);植皮组感觉恢复优9例(60.0%),良4例(26.0%),差2例(14.0%).创面愈合效果补片组优14例,良5例,差2例;植皮组愈合优9例,良4例,差2例.结论 SIS能快速、有效的刺激机体再生出表皮组织,并且新生的表皮经过生长与周围皮肤颜色无明显差异,无明显瘢痕增生,是一种手部小面积浅表软组织缺损的理想修复材料.     

Increased intracranial hemorrhage of mechanical thrombectomy in acute ischemic stroke patients with atrial fibrillation

Journal of Thrombosis and Thrombolysis - The impact of atrial fibrillation (AF) on outcomes of mechanical thrombectomy (MT) for acute ischemic stroke (AIS) is controversial, and with a paucity of...     

长链非编码RNA CBR3-AS1在胆管癌中的表达及其临床意义

目的:探讨长链非编码RNA CBR3-AS1(lncRNA CBR3-AS1)在胆管癌(CCA)中表达状态及其临床意义。方法:用qRT-PCR检测lncRNA CBR3-AS1在CCA组织与癌旁组织以及CCA细胞与正常胆管上皮细胞中的表达,分析lncRNA CBR3-AS1表达与CCA患者临床病理参数及生存率的关系。将胆管癌细胞分别转染lncRNA CBR3-AS1过表达质粒(过表达组)、阴性对照质粒(对照组)及lncRNA CBR3-AS1沉默序列(沉默组),用MTT实验与Transwell实验检测各组细胞的增殖与侵袭能力。结果:lncRNA CBR3-AS1的表达在胆管癌组织中明显高于癌旁组织,在胆管癌细胞系中明显高于正常胆管上皮细胞(均P0.01)。lncRNA CBR3-AS1表达与CCA患者淋巴结转移、TNM分期和术后复发明显有关(P0.05)。lncRNA CBR3-AS1高表达患者总生存率明显低于lncRNA CBR3-AS1低表达患者(P=0.004)。lncRNA CBR3-AS1表达(P=0.020)与TNM分期(P=0.014)是影响CCA患者总生存率的独立危险因素。与对照组CCA细胞比较,过表达组CCA细胞增殖与侵袭能力明显增高,沉默组CCA细胞增殖与侵袭能力明显降低(均P0.05)。结论:lncRNA CBR3-AS1在胆管癌中表达升高,升高的lncRNA CBR3-AS1与CCA的恶性临床病理特征及患者的不良预后密切相关。     

Poly(ADP-ribose) glycohydrolase silencing down-regulates TCTP and Cofilin-1 associated with metastasis in benzo(a)pyrene carcinogenesis

Benzo(a)pyrene (BaP) is a ubiquitously distributed environmental pollutant. BaP is a known carcinogen and can induce malignant transformation of rodent and human cells. Many evidences suggest that inhibitor of poly(ADP-ribose) glycohydrolase (PARG) is potent anticancer drug candidate. However, the effect of PARG on BaP carcinogenesis remains unclear. We explored this question in a PARG-deficient human bronchial epithelial cell line (shPARG cells) treated with various concentration of BaP for 15 weeks. Soft agar assay was used to examine BaP-induced cell malignancy of human bronchial epithelial cells and shPARG cells. Mechanistic investigations were used by 2D-DIGE and mass spectrometry. Western blot analysis and Double immunofluorescence detection were used to confirm some of the results obtained from DIGE experiments. We found that PARG silencing could dramatically inhibit BaP-induced cell malignancy of human bronchial epithelial cells in soft agar assay. Altered levels of expression induced by BaP were observed within shPARG cells for numerous proteins, including proteins required for cell mobility, stress response, DNA repair and cell proliferation pathways. Among these proteins, TCTP and Cofilin-1 involved in malignancy, were validated by western blot analysis and immunofluorescence assay. PARG inhibition contributed to down-regulation of TCTP and Cofilin-1. This is the first experimental demonstration of a link between PARG silencing and reduced cell migration after BaP exposure. We propose that PARG silencing might down-regulate TCTP and Cofilin-1 associated with metastasis in BaP carcinogenesis.